Related Experiment Video
Updated: May 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nucleoside/nucleotide analogue polymerase inhibitors in development
1Division of Gastroenterology/Hepatology, Liver Disease Center, Scripps Clinic, La Jolla, CA 92067, USA. pockros.paul@scrippshealth.org
Abstract:
Nucleoside/nucleotide analogue polymerase inhibitors (NPIs) are analogues of natural substrates that bind the active site of NS5B and terminate viral RNA chain generation and generally provide a high genetic barrier to resistance and are effective in all genotypes. NPIs such as sofosbuvir (GS-7977) show high antiviral activities that, together with their high genetic barrier to resistance, suggest that they are optimal backbone candidates for all-oral combination therapies. Several trials are ongoing to further define the potential of all-oral regimens with sofosbuvir (GS-7977). Recent interim analyses indicate that many patients treated with only 2 direct-acting antiviral agents experience viral breakthrough, which can be significantly reduced by the addition of ribavirin without pegylated interferon α.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Biosynthesis of Nucleic Acids
Inhibitors of Bacterial Protein Synthesis
Inhibition of Cdk Activity
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...

